

Paolo Caraceni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3084252/publications.pdf>

Version: 2024-02-01

155
papers

12,101
citations

34105

52
h-index

28297

105
g-index

161
all docs

161
docs citations

161
times ranked

10573
citing authors

#	ARTICLE	IF	CITATIONS
1	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2016, 65, 727-733.	3.7	768
2	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
3	Serum α -fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. <i>Journal of Hepatology</i> , 2001, 34, 570-575.	3.7	677
4	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	3.7	571
5	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	7.3	493
6	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	12.1	405
7	Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2012, 142, 782-789.e3.	1.3	355
8	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
9	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. <i>Hepatology</i> , 2013, 58, 1836-1846.	7.3	327
10	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
11	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	3.7	289
12	Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials. <i>Hepatology</i> , 2012, 55, 1172-1181.	7.3	285
13	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i> , 2015, 62, 567-574.	7.3	283
14	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
15	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
16	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
17	The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 670-685.	3.7	204
18	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	12.1	190

#	ARTICLE	IF	CITATIONS
19	Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patient. <i>Cancer</i> , 1995, 75, 2220-2232.	4.1	155
20	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 712-723.	0.9	155
21	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
22	Cardiac electrophysiological abnormalities in patients with cirrhosis. <i>Journal of Hepatology</i> , 2006, 44, 994-1002.	3.7	141
23	Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status. <i>Hepatology</i> , 2001, 33, 808-815.	7.3	138
24	Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2014, 60, 1851-1860.	7.3	135
25	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
26	Clinical indications for the albumin use: Still a controversial issue. <i>European Journal of Internal Medicine</i> , 2013, 24, 721-728.	2.2	133
27	Liver Transplantation from Donors Aged 80 Years and Over: Pushing the Limit. <i>American Journal of Transplantation</i> , 2004, 4, 1139-1147.	4.7	122
28	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , 2017, 49, 121-137.	0.9	111
29	Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 51-58.	3.7	104
30	A novel model of CCl4-induced cirrhosis with ascites in the mouse. <i>Journal of Hepatology</i> , 2009, 51, 991-999.	3.7	100
31	Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. <i>Gut</i> , 2018, 67, 1892-1899.	12.1	98
32	Gross pathologic types of hepatocellular carcinoma in Italian patients: Relationship with demographic, environmental, and clinical factors. <i>Cancer</i> , 1993, 72, 1557-1563.	4.1	94
33	The use of donor fatty liver for liver transplantation: a challenge or a quagmire?. <i>Journal of Hepatology</i> , 1996, 24, 114-121.	3.7	94
34	Starvation Impairs Antioxidant Defense in Fatty Livers of Rats Fed A Choline-Deficient Diet. <i>Journal of Nutrition</i> , 2000, 130, 2131-2136.	2.9	94
35	QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. <i>Journal of Hepatology</i> , 2003, 38, 461-467.	3.7	88
36	Effect of chronic β_2 -blockade on QT interval in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 415-421.	3.7	83

#	ARTICLE	IF	CITATIONS
37	The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. <i>Journal of Surgical Research</i> , 2005, 124, 160-168.	1.6	80
38	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
39	Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. <i>Hepatology</i> , 1999, 30, 1387-1392.	7.3	79
40	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	7.3	76
41	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
42	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
43	Lamivudine treatment for acute hepatitis B after liver transplantation. <i>Journal of Hepatology</i> , 1998, 29, 985-989.	3.7	71
44	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. <i>Liver International</i> , 2010, 30, 816-825.	3.9	69
45	Ischemia-reperfusion injury in rat fatty liver: Role of nutritional status. <i>Hepatology</i> , 1999, 29, 1139-1146.	7.3	67
46	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
47	Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. <i>Journal of Hepatology</i> , 2004, 41, 82-88.	3.7	64
48	Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. <i>European Radiology</i> , 2018, 28, 506-513.	4.5	63
49	Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors: First Italian Clinical Trial. <i>Scientific Reports</i> , 2020, 10, 6063.	3.3	61
50	Novel perspectives in the management of decompensated cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 753-764.	17.8	60
51	Clinical use of albumin. <i>Blood Transfusion</i> , 2013, 11 Suppl 4, s18-25.	0.4	59
52	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World Journal of Hepatology</i> , 2014, 6, 601.	2.0	59
53	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 113-120.	3.7	58
54	Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon β therapy. <i>Journal of Hepatology</i> , 1995, 23, 503-508.	3.7	57

#	ARTICLE	IF	CITATIONS
55	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.9	57
56	Food Deprivation Exacerbates Mitochondrial Oxidative Stress in Rat Liver Exposed to Ischemia-Reperfusion Injury. <i>Journal of Nutrition</i> , 2001, 131, 105-110.	2.9	54
57	Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis. <i>Laboratory Investigation</i> , 2012, 92, 384-395.	3.7	51
58	The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. <i>Liver International</i> , 2013, 33, 1298-1308.	3.9	50
59	INCREASED GENERATION OF REACTIVE OXYGEN SPECIES IN ISOLATED RAT FATTY LIVER DURING POSTISCHEMIC REOXYGENATION1. <i>Transplantation</i> , 2001, 71, 1816-1820.	1.0	48
60	Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. <i>Gut</i> , 2009, 58, 1135-1143.	12.1	48
61	<scp>QT</scp> interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1510-1515.	3.9	48
62	Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 817-828.	3.7	48
63	Cannabinoid Type 1 Receptor Antagonism Delays Ascites Formation in Rats With Cirrhosis. <i>Gastroenterology</i> , 2009, 137, 341-349.	1.3	46
64	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	3.7	45
65	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. <i>Hepatology</i> , 2021, 74, 2058-2073.	7.3	45
66	Structural and functional integrity of human serum albumin: Analytical approaches and clinical relevance in patients with liver cirrhosis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 144, 138-153.	2.8	43
67	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1533-1540.	2.4	40
68	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
69	OXYGEN FREE RADICAL CONTENT AND NEUTROPHIL INFILTRATION ARE IMPORTANT DETERMINANTS IN MUCOSAL INJURY AFTER RAT SMALL BOWEL TRANSPLANTATION. <i>Transplantation</i> , 1996, 62, 161-166.	1.0	38
70	Cryoglobulinemia: a cause for false negative polymerase chain reaction results in patients with hepatitis C virus positive chronic liver disease. <i>Journal of Hepatology</i> , 1995, 22, 464-467.	3.7	37
71	The role of the endocannabinoid system in liver diseases. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 65-77.	4.7	37
72	Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. <i>Scientific Reports</i> , 2016, 6, 35987.	3.3	35

#	ARTICLE	IF	CITATIONS
73	Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 1116-1127.	3.7	31
74	Prevention of Reoxygenation Injury by Sodium Salicylate in Isolated-Perfused Rat Liver. <i>Free Radical Biology and Medicine</i> , 1998, 25, 87-94.	2.9	30
75	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021, 75, S118-S134.	3.7	30
76	Mass spectrometric characterization of human serum albumin dimer: A new potential biomarker in chronic liver diseases. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 112, 169-175.	2.8	29
77	Extended Infusion of \hat{I}^2 -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1731-1739.	5.8	29
78	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. <i>Nutrients</i> , 2021, 13, 2748.	4.1	28
79	How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. <i>World Journal of Gastroenterology</i> , 2011, 17, 3479.	3.3	26
80	Arterialization of the Portal Vein in a Patient with a Dearterialized Liver Graft and Massive Necrosis. <i>New England Journal of Medicine</i> , 2001, 345, 1352-1353.	27.0	25
81	Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. <i>Digestive and Liver Disease</i> , 2011, 43, 242-245.	0.9	25
82	Soluble Receptor Activator of Nuclear Factor- \hat{I}^B Ligand (sRANKL)/Osteoprotegerin Balance in Ageing and Age-Associated Diseases. <i>Biogerontology</i> , 2004, 5, 119-127.	3.9	24
83	AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 4-15.	0.9	24
84	Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts. <i>Annals of Transplantation</i> , 2018, 23, 34-44.	0.9	24
85	Effect of ethanol on adenosine triphosphate, cytosolic free calcium, and cell injury in rat hepatocytes. <i>Digestive Diseases and Sciences</i> , 1996, 41, 2204-2212.	2.3	23
86	Daily profile of plasma endothelial-1 and -3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal functin. <i>Journal of Hepatology</i> , 1997, 26, 808-815.	3.7	22
87	Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. <i>Hepatology</i> , 2020, 71, 1106-1116.	7.3	22
88	Systemic and regional hemodynamics in pre-ascitic cirrhosis: effects of posture. <i>Journal of Hepatology</i> , 2003, 39, 502-508.	3.7	20
89	Variable activation of phosphoinositide 3-kinase influences the response of liver grafts to ischemic preconditioning. <i>Journal of Hepatology</i> , 2009, 50, 937-947.	3.7	20
90	Ischaemiaâ€modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. <i>Liver International</i> , 2015, 35, 2425-2432.	3.9	20

#	ARTICLE	IF	CITATIONS
91	Successful Treatment of CCl ₄ -Induced Acute Liver Failure With Portal Vein Arterialization in the Rat. <i>Journal of Surgical Research</i> , 2006, 135, 394-401.	1.6	19
92	Specific issues concerning the management of patients on the waiting list and after liver transplantation. <i>Liver International</i> , 2018, 38, 1338-1362.	3.9	19
93	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
94	Portal hypertension and liver cirrhosis in rats: effect of the β_3 -adrenoceptor agonist SR58611A. <i>British Journal of Pharmacology</i> , 2012, 167, 1137-1147.	5.4	17
95	Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 122, 141-147.	2.8	16
96	The Analysis of Food Intake in Patients with Cirrhosis Waiting for Liver Transplantation: A Neglected Step in the Nutritional Assessment. <i>Nutrients</i> , 2019, 11, 2462.	4.1	16
97	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
98	Long-term albumin treatment in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2022, 76, 1306-1317.	3.7	16
99	Ascites apheresis, concentration and reinfusion for the treatment of massive or refractory ascites in cirrhosis. <i>Journal of Hepatology</i> , 1994, 20, 289-295.	3.7	15
100	Portal Vein Arterialization in a Patient with Acute Liver Failure. <i>Transplantation</i> , 2005, 79, 851-852.	1.0	15
101	A novel sodium overload test predicting ascites decompensation in rats with CCl ₄ -induced cirrhosis. <i>Journal of Hepatology</i> , 2005, 43, 92-97.	3.7	14
102	Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. <i>Digestive and Liver Disease</i> , 2007, 39, 943-951.	0.9	14
103	Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 11, 1-2.	3.0	14
104	The use of human albumin in patients with cirrhosis: a European survey. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 625-632.	3.0	14
105	Management of Ascites in Patients with Cirrhosis: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 5226.	2.4	14
106	Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?. <i>Liver International</i> , 2013, 33, 488-493.	3.9	13
107	AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. <i>Blood Transfusion</i> , 2016, 14, 8-22.	0.4	13
108	Role of p38 map kinase in glycine-induced hepatocyte resistance to hypoxic injury. <i>Journal of Hepatology</i> , 2007, 46, 692-699.	3.7	12

#	ARTICLE	IF	CITATIONS
109	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. <i>JHEP Reports</i> , 2019, 1, 270-277.	4.9	12
110	Hypothermic Oxygenated Perfusion Versus Static Cold Storage for Expanded Criteria Donors in Liver and Kidney Transplantation: Protocol for a Single-Center Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e13922.	1.0	12
111	Accesses for alcohol intoxication to the emergency department and the risk of re-hospitalization: An observational retrospective study. <i>Addictive Behaviors</i> , 2018, 77, 1-6.	3.0	11
112	Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1367-1369.	2.4	11
113	Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. <i>Journal of Hepatology</i> , 2008, 48, 559-566.	3.7	10
114	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. <i>Liver International</i> , 2017, 37, 678-683.	3.9	10
115	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
116	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2021, 53, 1089-1104.	0.9	10
117	Effect of vitamin E on reoxygenation injury experienced by isolated rat hepatocytes. <i>Life Sciences</i> , 1994, 55, 1427-1432.	4.3	9
118	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
119	Corrigendum to "Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites" [<i>J Hepatol</i> 2015;62:968-974]. <i>Journal of Hepatology</i> , 2015, 63, 290.	3.7	9
120	Pro: The Role of Albumin in Pre-Liver Transplant Management. <i>Liver Transplantation</i> , 2019, 25, 128-134.	2.4	9
121	Albumin: Indications in chronic liver disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 528-535.	3.8	9
122	Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: Relationship with renal function. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 642-647.	1.5	7
123	A Case of Prolonged Cholestatic Hepatitis Induced by Azithromycin in a Young Woman. <i>Case Reports in Hepatology</i> , 2011, 2011, 1-4.	0.7	7
124	Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. <i>Digestive and Liver Disease</i> , 2013, 45, 516-522.	0.9	7
125	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. <i>Cytotherapy</i> , 2017, 19, 1447-1461.	0.7	7
126	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.9	7

#	ARTICLE	IF	CITATIONS
127	A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic. <i>Digestive and Liver Disease</i> , 2020, 52, 956-957.	0.9	7
128	Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 147-158.	0.9	7
129	The Nutritional Status Modulates Preservation-Reperfusion Injury in Rat Fatty Liver. <i>Journal of Surgical Research</i> , 2005, 127, 190-196.	1.6	6
130	The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. <i>Health Economics Review</i> , 2019, 9, 22.	2.0	6
131	The Italian compassionate use of sofosbuvir in <scp>HCV</scp> patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018, 38, 733-741.	3.9	5
132	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. <i>Journal of Hepatology</i> , 2019, 70, e53.	3.7	5
133	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.9	5
134	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
135	Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal. <i>Pharmaceuticals</i> , 2022, 15, 645.	3.8	5
136	Liver Cirrhosis in a Patient with Sickle Cell Trait (Hb Sβ+Thalassemia) without Other Known Causes of Hepatic Disease. <i>Case Reports in Gastroenterology</i> , 2009, 3, 275-279.	0.6	4
137	Simple and rapid LC-MS method for the determination of circulating albumin microheterogeneity in veal calves exposed to heat stress. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 144, 263-268.	2.8	4
138	Low Adherence To Nutritional Recommendations In Patients With Cirrhosis: A Prospective Observational Study. <i>Journal of Gastroenterology and Hepatology Research</i> , 2019, 8, 2896-2902.	0.2	4
139	Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference. <i>Annals of Translational Medicine</i> , 2019, 7, S201-S201.	1.7	4
140	Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. <i>Journal of Clinical Medicine</i> , 2021, 10, 4590.	2.4	4
141	AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update. <i>Blood Transfusion</i> , 2021, 19, 9-13.	0.4	4
142	Skills and Requirements of a Transplant Hepatologist: Board Certification of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2013, 45, 992-994.	0.9	3
143	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2
144	Hyposplenism as a cause of pneumococcal meningococcal meningitis in an adult patient with coeliac disease. <i>Italian Journal of Medicine</i> , 2011, 5, 124-127.	0.3	1

#	ARTICLE	IF	CITATIONS
145	Dorsal acoustic windows may ameliorate liver ultrasound in patients with chronic liver disease and meteorism/obesity/ascites. <i>Journal of Medical Ultrasonics</i> (2001), 2013, 40, 399-408.	1.3	1
146	CD133+ Pluripotent Stem Cells for the Treatment of Chronic Liver Failure.. <i>Blood</i> , 2010, 116, 1185-1185.	1.4	1
147	Acute and chronic sinusitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 1153-1156.	1.6	0
148	Response to The reduced CO_2 binding ability of ischaemia-modified albumin is unlikely to be because of oxidative modification of the N-terminus. <i>Liver International</i> , 2015, 35, 2623-2624.	3.9	0
149	Questions in the design of ANSWER – Authors' reply. <i>Lancet</i> , The, 2018, 392, 1623-1624.	13.7	0
150	PS-102-Circulating native albumin in patients with cirrhosis admitted to hospital for acute decompensation and acute-on-chronic liver failure: Relation to serum albumin levels, albumin function, and patient outcomes. <i>Journal of Hepatology</i> , 2019, 70, e65.	3.7	0
151	Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S211-S212.	3.7	0
152	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. <i>Journal of Hepatology</i> , 2020, 73, S738.	3.7	0
153	Bacterial infections in patients with liver cirrhosis. <i>Reviews in Health Care</i> , 2011, 2, 147-159.	0.1	0
154	The use of albumin in the complications of cirrhosis: evidence and future perspectives. <i>Reviews in Health Care</i> , 2013, 4, 159-173.	0.1	0
155	Letter to the editor: RECAM for the diagnosis of DILI – Is it time to incorporate additional pharmacological criteria?. <i>Hepatology</i> , 2022, 76, E25-E26.	7.3	0